Long-term real-world data of ustekinumab in Crohn's disease: the Stockholm ustekinumab study.

Francesca BelloSamer MuhsenHaider SabhanAlexandra BorinFredrik JohanssonCharlotte HöögOle ForsbergChristina WennerströmCharlotte SödermanMikael LördalSven Almer

Published in: Therapeutic advances in gastroenterology (2024)

Among difficult-to-treat patients with CD, ustekinumab was effective in the majority, with high drug persistence at 12 and 24 months in combination with a favourable safety profile.

Keyphrases

electronic health record
emergency department
adverse drug